- Home
- HNRG vs PRTA Comparison
HNRG vs PRTA Comparison
Compare HNRG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- PRTA
- Stock Information
- Founded
- HNRG 1949
- PRTA 2012
- Country
- HNRG United States
- PRTA Ireland
- Employees
- HNRG N/A
- PRTA N/A
- Industry
- HNRG Coal Mining
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- PRTA Health Care
- Exchange
- HNRG Nasdaq
- PRTA Nasdaq
- Market Cap
- HNRG 551.9M
- PRTA 643.0M
- IPO Year
- HNRG N/A
- PRTA N/A
- Fundamental
- Price
- HNRG $12.79
- PRTA $14.11
- Analyst Decision
- HNRG Strong Buy
- PRTA Buy
- Analyst Count
- HNRG 2
- PRTA 7
- Target Price
- HNRG $15.00
- PRTA $46.50
- AVG Volume (30 Days)
- HNRG 382.2K
- PRTA 672.2K
- Earning Date
- HNRG 03-12-2025
- PRTA 02-13-2025
- Dividend Yield
- HNRG N/A
- PRTA N/A
- EPS Growth
- HNRG N/A
- PRTA N/A
- EPS
- HNRG N/A
- PRTA N/A
- Revenue
- HNRG $429,359,000.00
- PRTA $133,350,000.00
- Revenue This Year
- HNRG N/A
- PRTA $56.89
- Revenue Next Year
- HNRG $7.22
- PRTA N/A
- P/E Ratio
- HNRG N/A
- PRTA N/A
- Revenue Growth
- HNRG N/A
- PRTA N/A
- 52 Week Low
- HNRG $4.33
- PRTA $11.70
- 52 Week High
- HNRG $14.00
- PRTA $34.65
- Technical
- Relative Strength Index (RSI)
- HNRG 62.82
- PRTA 50.40
- Support Level
- HNRG $12.26
- PRTA $13.00
- Resistance Level
- HNRG $12.85
- PRTA $14.40
- Average True Range (ATR)
- HNRG 0.64
- PRTA 0.99
- MACD
- HNRG 0.13
- PRTA 0.04
- Stochastic Oscillator
- HNRG 85.25
- PRTA 59.11
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).